Investors focused on the Medical space have likely heard of Champions Oncology (CSBR Quick QuoteCSBR - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? Let's take a closer look at the stock's year-to-date performance to find out.

Champions Oncology is a member of the Medical sector. This group includes 818 individual stocks and currently holds a Zacks Sector Rank of #2. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.

The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. CSBR is currently sporting a Zacks Rank of #1 (Strong Buy).

Within the past quarter, the Zacks Consensus Estimate for CSBR's full-year earnings has moved 277.78% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.

Based on the most recent data, CSBR has returned 218.04% so far this year. In comparison, Medical companies have returned an average of 2.71%. As we can see, Champions Oncology is performing better than its sector in the calendar year.

Breaking things down more, CSBR is a member of the Medical - Drugs industry, which includes 171 individual companies and currently sits at #79 in the Zacks Industry Rank. Stocks in this group have lost about 4.01% so far this year, so CSBR is performing better this group in terms of year-to-date returns.

Investors with an interest in Medical stocks should continue to track CSBR. The stock will be looking to continue its solid performance.